Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial

Author:

Hannoun-Levi Jean-Michel,Chand-Fouche Marie-Eve,Pace-Loscos Tanguy,Gautier Mathieu,Gal Jocelyn,Schiappa Renaud,Pujol Nina

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference24 articles.

1. Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=27&single_unit=50000. Access on line 21/03/22.

2. National Comprehensive Cancer network. Prostate Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Access on line 21/03/22.

3. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA,1998

4. UROGEC group of GEC ESTRO ith endorsement by the European association of urology. GEC-ESTRO ACROP prostate brachytherapy guidelines;Henry;Radiother. Oncol.,2022

5. High dose rate brachytherapy as prostate cancer mono therapy reduces toxicity compared to low dose rate palladium seeds;Grills;J Uol,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3